Evaluation and characterization of tumor lysis syndrome before and after chemotherapy among pediatric oncology patients in Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia
Autor: | Haileleul Micho, Solomon Genet, Daniel Hailu, Yasin Mohammed |
---|---|
Rok vydání: | 2017 |
Předmět: |
0301 basic medicine
Cell death medicine.medical_specialty medicine.medical_treatment Pediatric oncology 03 medical and health sciences Hyperphosphatemia 0302 clinical medicine Internal medicine Medicine Hyperuricemia Prospective cohort study Molecular Biology Tumor lysis syndrome Chemotherapy Hematology lcsh:RC633-647.5 business.industry Incidence (epidemiology) lcsh:Diseases of the blood and blood-forming organs medicine.disease 030104 developmental biology 030220 oncology & carcinogenesis business Complication Biomarkers Research Article |
Zdroj: | BMC Hematology BMC Hematology, Vol 18, Iss 1, Pp 1-7 (2018) |
ISSN: | 2052-1839 |
Popis: | Background Tumor lysis syndrome (TLS) is a life-threatening emergency disorder, caused by an abrupt release of intracellular metabolites after tumor cell death. It is characterized by a series of metabolic manifestations, especially hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia. The aim of this study was to evaluate and characterize the incidence of tumor lysis syndrome among pediatric oncology patients before and after treatment. Methods Hospital based prospective cohort study was conducted for 6 months on 61 newly diagnosed pediatric oncology patients. Socio-demographic data was collected by interview administered questionnaire. Patients were followed and the physical diagnosis, imaging and laboratory results were interpreted by senior physicians. Data was entered to and analyzed by SPSS version 23. Results Among 61 pediatric oncology patients 39(63.9%) were males. The mean (±SD) age of the pediatric patients was 6.39 (± 3.67) years ranging from 2 months to 14 years. 29.5% of patients were found to have TLS. There were 11.5% and 18.0% of laboratory TLS (LTLS) and clinical TLS (CTLS) cases respectively. There were72.2% spontaneous and 27.8% treatment induced TLS cases with 23% and 21.3% cases of hyperuricemia and 4.9% and 6.6% cases of hyperkalemia incidence before and after treatment respectively. Only two patients died, in the study period, due to TLS. Conclusion There was high incidence of TLS irrespective of socio-demographic variation among study participants, suggesting that children with cancer are at risk of developing TLS. As TLS is a life-threatening complication of malignancies, early identification of patients at risk and reducing morbidity and mortality is crucially important. |
Databáze: | OpenAIRE |
Externí odkaz: |